PYC: Multiple clinical readouts and a strong safety profile drive momentum toward late-stage trials

Upcoming 18 months will see multiple human safety and efficacy readouts across four clinical programs, with the PKD program advancing toward registrational studies and showing a clean safety profile so far. Organizational expansion and capital strength position the company for late-stage developmen…